Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients.
Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of 56.4 ± 9.1 years) divided into the placebo and RSV-treatment groups was performed. 50 mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients.
Lycotec Ltd, Granta Park, Platinum Building, Cambridge CB21 6GP, UK.
Yuriy K
YK
Bashmakov
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt.
Samir H
SH
Assaad-Khalil
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt.
Myriam
M
Abou Seif
Clinical Epidemiology and Biostatistics, Örebro University Hospital and School of Health and Medical Sciences, Örebro University, Örebro, Sweden.
Ruzan
R
Udumyan
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt.
Magdy
M
Megallaa
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt.
Kamel H
KH
Rohoma
Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt.
Mohamed
M
Zeitoun
Lycotec Ltd, Granta Park, Platinum Building, Cambridge CB21 6GP, UK.
Ivan M
IM
Petyaev